JP2004515218A - プロモータへ隣接する遺伝子から保護抗原を発現する呼吸器系合胞体ウイルスワクチン - Google Patents

プロモータへ隣接する遺伝子から保護抗原を発現する呼吸器系合胞体ウイルスワクチン Download PDF

Info

Publication number
JP2004515218A
JP2004515218A JP2002505815A JP2002505815A JP2004515218A JP 2004515218 A JP2004515218 A JP 2004515218A JP 2002505815 A JP2002505815 A JP 2002505815A JP 2002505815 A JP2002505815 A JP 2002505815A JP 2004515218 A JP2004515218 A JP 2004515218A
Authority
JP
Japan
Prior art keywords
rsv
gene
genome
antigenome
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002505815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004515218A5 (enExample
Inventor
ディー． クレンプル，クリスティーン
エル． コリンズ，ピーター
アール． マーフィー，ブライアン
ブフホルツ，ウルズラ
エス． ホワイトヘッド，スティーブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2004515218A publication Critical patent/JP2004515218A/ja
Publication of JP2004515218A5 publication Critical patent/JP2004515218A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002505815A 2000-06-23 2001-06-22 プロモータへ隣接する遺伝子から保護抗原を発現する呼吸器系合胞体ウイルスワクチン Pending JP2004515218A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21370800P 2000-06-23 2000-06-23
PCT/US2001/020107 WO2002000693A2 (en) 2000-06-23 2001-06-22 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes

Publications (2)

Publication Number Publication Date
JP2004515218A true JP2004515218A (ja) 2004-05-27
JP2004515218A5 JP2004515218A5 (enExample) 2008-08-21

Family

ID=22796187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002505815A Pending JP2004515218A (ja) 2000-06-23 2001-06-22 プロモータへ隣接する遺伝子から保護抗原を発現する呼吸器系合胞体ウイルスワクチン

Country Status (13)

Country Link
EP (1) EP1294858B1 (enExample)
JP (1) JP2004515218A (enExample)
KR (1) KR100899030B1 (enExample)
CN (1) CN1468301A (enExample)
AT (1) ATE416251T1 (enExample)
AU (3) AU6870901A (enExample)
BR (1) BRPI0112276B8 (enExample)
CA (1) CA2413786A1 (enExample)
DE (1) DE60136811D1 (enExample)
ES (1) ES2317914T3 (enExample)
IL (1) IL153530A0 (enExample)
MX (1) MXPA02012818A (enExample)
WO (1) WO2002000693A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544322A (ja) * 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
JP2018537103A (ja) * 2015-12-11 2018-12-20 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズＴｈｅ Ｕ．Ｓ．Ａ．Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｈｅａｌｔｈ Ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ Ｎｓ１およびｎｓ２遺伝子シフトを含む組換えｒｓウイルス株

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530073A (ja) * 1999-07-09 2003-10-14 アメリカ合衆国 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造
WO2008094197A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
CN105200069A (zh) * 2015-10-16 2015-12-30 北京交通大学 基于rna聚合酶ⅰ的rsv微型复制基因组及其应用
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002530A1 (en) * 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002530A1 (en) * 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544322A (ja) * 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
JP2015015954A (ja) * 2006-07-27 2015-01-29 タケダ ヴァクシーンズ， インコーポレイテッド キメラウイルス様粒子
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
JP2018537103A (ja) * 2015-12-11 2018-12-20 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズＴｈｅ Ｕ．Ｓ．Ａ．Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｈｅａｌｔｈ Ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ Ｎｓ１およびｎｓ２遺伝子シフトを含む組換えｒｓウイルス株
JP7063808B2 (ja) 2015-12-11 2022-05-09 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎｓ１およびｎｓ２遺伝子シフトを含む組換えｒｓウイルス株
JP7063808B6 (ja) 2015-12-11 2022-06-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎｓ１およびｎｓ２遺伝子シフトを含む組換えｒｓウイルス株

Also Published As

Publication number Publication date
BRPI0112276B1 (pt) 2019-12-31
ATE416251T1 (de) 2008-12-15
ES2317914T3 (es) 2009-05-01
CA2413786A1 (en) 2002-01-03
CN1468301A (zh) 2004-01-14
IL153530A0 (en) 2003-07-06
DE60136811D1 (de) 2009-01-15
EP1294858B1 (en) 2008-12-03
KR100899030B1 (ko) 2009-05-21
AU6870901A (en) 2002-01-08
KR20030045685A (ko) 2003-06-11
WO2002000693A3 (en) 2002-09-26
BRPI0112276B8 (pt) 2021-05-25
MXPA02012818A (es) 2003-05-14
WO2002000693A2 (en) 2002-01-03
AU2006252238A1 (en) 2007-01-25
EP1294858A2 (en) 2003-03-26
AU2001268709B2 (en) 2006-09-28
BR0112276A (pt) 2004-02-10

Similar Documents

Publication Publication Date Title
KR100905450B1 (ko) 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법
EP2112220A2 (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) Attenuated chimeric respiratory syncytial virus
CN100491530C (zh) 从克隆的核苷酸序列制备减毒嵌合呼吸道合胞病毒疫苗
US6923971B2 (en) Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US7744902B2 (en) Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
WO2001004321A1 (en) Production of attenuated respiratory syncytial virus vaccines involving modification of m2 orf2
KR100899030B1 (ko) 프로모터 인접 유전자로부터 보호적 항원을 발현하는호흡기 신시티움 바이러스 백신
US7662397B2 (en) Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
AU2001268709A1 (en) Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
US7820182B2 (en) Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
AU2005201040A1 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120403